Overview Latest Regional Industry Featured Multimedia Other Languages Public Company News
All APAC Global
All APAC Global
All APAC Global
All APAC Global
Tigermed Reports 2023 Interim Results 2023-08-25 18:39
GC Biopharma to Produce Cholera Vaccines Jointly with Eubiologics 2023-08-25 15:14
Akeso Announced NDA Acceptance of IL-12/lL-23 Monoclonal Antibody Ebdarokimab for Moderate-to-severe Plaque Psoriasis by China NMPA 2023-08-24 20:00
111, Inc. Announces Second Quarter 2023 Unaudited Financial Results 2023-08-24 14:00
PeptiGrowth Inc. and Orizuru Therapeutics, Inc. Enter into Joint Development of Novel Synthetic Peptide Based Growth Factor 2023-08-24 09:51
Samsung Biologics appoints new leadership to oversee quality and regulatory affairs 2023-08-24 07:59
Maypharm Launches the world first Adipose Stem Cell Exosome hair filler, HAIRNA Exosome Hair Fill 2023-08-23 17:00
ImmVira Appoints Howard L. Kaufman, M.D. as Consulting Medical Advisor 2023-08-23 10:51
Asieris Pharmaceuticals Unveils 2023 Semi-Annual Report, Demonstrating Initial Success of Specialty Pharma Strategy and Multi-Product Synergistic Commercialization 2023-08-22 20:58
Sanyou Biopharmaceuticals and Sinorda Biomedicine signed Strategic Cooperation Agreement for Advancing Innovative Drug Research and Development 2023-08-22 20:00
CARsgen Announced 2023 Interim Results 2023-08-22 19:30
Kintor Pharma Announces Completion of Patient Enrollment in Phase II Clinical Trial of GT20029 for Treatment of Androgenetic Alopecia in China 2023-08-22 17:13
Introducing NeoMab™: GemPharmatech's Innovative Antibody Gene Humanized Mouse Model 2023-08-22 08:59
CanariaBio Achieves Significant Milestone with FDA's Orphan Drug Designation for MAb-AR20.5 Targeting Pancreatic Cancer 2023-08-21 20:00
TradeUP Acquisition Corp. Announces Extension of the Deadline for an Initial Business Combination 2023-08-19 04:30
Akeso Announced First Patient Dosed in Phase 3 Trial of Ivonescimab versus Tislelizumab for First-line Treatment of Squamous NSCLC 2023-08-18 20:00
Inmagene's anti-OX40 mAb demonstrated an extended half-life and a favorable safety profile in a Phase I study 2023-08-18 19:00
JinMed (NASDAQ: ZJYL) Rings the Nasdaq Stock Market Closing Bell on August 17 2023-08-18 11:36
Thrombotic AEs of Hemlibra (emicizumab) were 2.8 times more frequent than those of FVIII replacements. 2023-08-18 08:58
Neurophth Announces First Patient Dosed in Phase I/II Clinical Trial of Second Gene Therapy 2023-08-17 21:00
1 40 41 42 43 44 165